Fumagillin
Based on 1 publication(s) in Google Scholar
Fumagillin(NSC9168) is an antimicrobial compound first isolated in 1949 from the fungus Aspergillus fumigatu. Fumagillin can inhibits HIV‐1 infection through the inhibition of HIV-1 viral protein R (Vpr) activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 95.04%
- No. CAS: 23110-15-8
- Fòrmula: C26H34O7
- Peso molecular:458.54
-
Almacenamiento:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Fumagillin
MoreVer todos los productos específicos de isoformas Parasite
MoreVer todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
|
HIV-1 |
Amebae |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | IC50 |
5 μM
Compound: 1b (Fumagillin)
|
Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells
Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells
|
[PMID: 12031320] |
| A-431 | IC50 |
48 μM
Compound: 2 (Fumagillin)
|
In vitro antiproliferative effect against A431 human epidermoid carcinoma cells
In vitro antiproliferative effect against A431 human epidermoid carcinoma cells
|
10.1016/S0960-894X(96)00564-1 |
| A549 | IC50 |
≥50 μM
Compound: Fumagillin
|
Antiproliferative activity against human A549 cells after 96 hrs by MTT assay
Antiproliferative activity against human A549 cells after 96 hrs by MTT assay
|
[PMID: 20974505] |
| CPAE | IC50 |
0.37 ng/mL
Compound: 1
|
Tested in vitro for its ability to inhibit cell proliferation of calf pulmonary artery endothelial cells measured calorimetrically by SRB method
Tested in vitro for its ability to inhibit cell proliferation of calf pulmonary artery endothelial cells measured calorimetrically by SRB method
|
[PMID: 10636239] |
| EL4 | IC50 |
0.42 ng/mL
Compound: 1
|
Tested in vitro for its ability to inhibit cell proliferation of lymphoma EL-4 cells measured calorimetrically by MTT method
Tested in vitro for its ability to inhibit cell proliferation of lymphoma EL-4 cells measured calorimetrically by MTT method
|
[PMID: 10636239] |
| HUVEC | EC50 |
0.82 nM
Compound: 1
|
Tested for inhibition of the human umbilical vein endothelial cell (HUVEC) proliferation
Tested for inhibition of the human umbilical vein endothelial cell (HUVEC) proliferation
|
[PMID: 14684305] |
| HUVEC | IC50 |
0.023 μg/mL
Compound: Fumagillin
|
Antiinvasive activity against HUVEC assessed as inhibition of cell migration after 6 hrs by Matrigel assay
Antiinvasive activity against HUVEC assessed as inhibition of cell migration after 6 hrs by Matrigel assay
|
[PMID: 20056543] |
| HUVEC | IC50 |
0.034 μg/mL
Compound: Fumagillin
|
Antiangiogenic activity against HUVEC cells assessed as inhibition of vascular formation after 6 hrs by wound healing assay
Antiangiogenic activity against HUVEC cells assessed as inhibition of vascular formation after 6 hrs by wound healing assay
|
[PMID: 20056543] |
| HUVEC | IC50 |
0.0089 μM
Compound: Fumagillin
|
Antiangiogenic activity in HUVEC after 96 hrs by MTT assay
Antiangiogenic activity in HUVEC after 96 hrs by MTT assay
|
[PMID: 20974505] |
| HUVEC | IC50 |
8.9 nM
Compound: Fumagillin
|
Antiproliferative activity against human HUVEC cells after 96 hrs by MTT assay
Antiproliferative activity against human HUVEC cells after 96 hrs by MTT assay
|
[PMID: 21296467] |
| HUVEC | IC50 |
6.6 nM
Compound: 1
|
Antiproliferative against HUVEC cells assessed as cell viability after 96 hrs by MTT assay
Antiproliferative against HUVEC cells assessed as cell viability after 96 hrs by MTT assay
|
[PMID: 24211639] |
| L1210 | IC50 |
8 μM
Compound: 1b (Fumagillin)
|
Inhibitory activity against proliferation of murine leukemia (L1210) cells
Inhibitory activity against proliferation of murine leukemia (L1210) cells
|
[PMID: 12031320] |
| MCF7 | IC50 |
≥50 μM
Compound: Fumagillin
|
Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
|
[PMID: 20974505] |
| P388 | IC50 |
>1 ng/mL
Compound: 1
|
Tested in vitro for its ability to inhibit cell proliferation of murine leukemia P388D1 cells measured calorimetrically by MTT method
Tested in vitro for its ability to inhibit cell proliferation of murine leukemia P388D1 cells measured calorimetrically by MTT method
|
[PMID: 10636239] |
| P388 | IC50 |
>=10 μg/mL
Compound: Fumagillin (1)
|
Inhibitory concentration against Murine leukemia P388 measured for endothelial cell proliferation activity
Inhibitory concentration against Murine leukemia P388 measured for endothelial cell proliferation activity
|
[PMID: 15978809] |
Fumagillin is an active amebicide and anti-infective isolated from the fungus Aspergillus fumigatus. Fumagillin does exhibit some side effects that have deterred its acceptance as a viable treatment, but the current body of research on the synthesis of novel analogs of this molecule shows an exciting and promising revival of this drug as both an anti-infective and antiangiogenic agent [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 23110-15-8
-
Appearance Solid
-
Peso molecular 458.54
-
Fòrmula C26H34O7
-
Color White to light yellow
-
SMILES
C[C@]1([C@@H](C/C=C(C)/C)O1)[C@]([C@@H]2OC)([H])[C@]3(CC[C@H]2OC(/C=C/C=C/C=C/C=C/C(O)=O)=O)CO3
-
Synonyms
Amebacilin; NSC9168
-
Structure Classification
-
Initial Source
Aspergillus
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Immunohorizons
Sustained monocyte activation by persistent challenges with either oxLDL or free cholesterol and underlying mechanisms. [Abstract]2026 Feb 24;10(2):vlag005. PMID: 41732084
Solvente y solubilidad
DMSO : 125 mg/mL (272.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 5 mg/mL (10.90 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (270 KB)
-
SDS (537 KB)
- English - EN (537 KB)
- Français - FR (537 KB)
- Deutsch - DE (537 KB)
- Norwegian - NO (537 KB)
- Español - ES (537 KB)
- Swedish - SV (537 KB)
- Italian - IT (537 KB)
- Korean - KR (537 KB)
- Portuguese - PT (537 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Lefkove, B., B. Govindarajan, and J.L. Arbiser, Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors. Expert Rev Anti Infect Ther, 2007. 5(4): p. 573-9. [Content Brief]
[2]. Watanabe N, et al. Fumagillin suppresses HIV-1 infection of macrophages through the inhibition of Vpr activity. FEBS Lett. 2006 May 15;580(11):2598-602. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1808 mL | 10.9042 mL | 21.8083 mL | 54.5209 mL |
| 5 mM | 0.4362 mL | 2.1808 mL | 4.3617 mL | 10.9042 mL | |
| 10 mM | 0.2181 mL | 1.0904 mL | 2.1808 mL | 5.4521 mL | |
| 15 mM | 0.1454 mL | 0.7269 mL | 1.4539 mL | 3.6347 mL | |
| 20 mM | 0.1090 mL | 0.5452 mL | 1.0904 mL | 2.7260 mL | |
| 25 mM | 0.0872 mL | 0.4362 mL | 0.8723 mL | 2.1808 mL | |
| 30 mM | 0.0727 mL | 0.3635 mL | 0.7269 mL | 1.8174 mL | |
| 40 mM | 0.0545 mL | 0.2726 mL | 0.5452 mL | 1.3630 mL | |
| 50 mM | 0.0436 mL | 0.2181 mL | 0.4362 mL | 1.0904 mL | |
| 60 mM | 0.0363 mL | 0.1817 mL | 0.3635 mL | 0.9087 mL | |
| 80 mM | 0.0273 mL | 0.1363 mL | 0.2726 mL | 0.6815 mL | |
| 100 mM | 0.0218 mL | 0.1090 mL | 0.2181 mL | 0.5452 mL |
Fumagillin Related Classifications
HY-B0751 Related Classifications
Powered by Bioz